Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC?
Introduction:: Interstitial cystitis/bladder pain syndrome (IC/BPS) pathophysiology is not fully understood. Vascular endothelial growth factor (VEGF) has been implicated in bladder vasculature alterations and nociception, but the role of its soluble receptor, VEGFR1, remains poorly explored. This s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Continence |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772973725001559 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210017730363392 |
|---|---|
| author | Pedro Abreu-Mendes Rui Almeida Pinto Diogo Dias Francisco Cruz Ana Charrua |
| author_facet | Pedro Abreu-Mendes Rui Almeida Pinto Diogo Dias Francisco Cruz Ana Charrua |
| author_sort | Pedro Abreu-Mendes |
| collection | DOAJ |
| description | Introduction:: Interstitial cystitis/bladder pain syndrome (IC/BPS) pathophysiology is not fully understood. Vascular endothelial growth factor (VEGF) has been implicated in bladder vasculature alterations and nociception, but the role of its soluble receptor, VEGFR1, remains poorly explored. This study aimed to determine whether urinary VEGF and VEGFR1 levels could be biomarkers for IC/BPS. As a post hoc analysis, we also examined VEGFR1 variation and its relationship with the clinical characteristics of IC/BPS patients and urinary serotonin levels. Material and Methods:: An observational cross-sectional pilot study was conducted after clearance from the ethics committee. Eighteen female IC/BPS patients and 19 healthy age-matched females without past urological conditions were included. ESSIC criteria were used to phenotype. The patient’s symptoms evaluated were bladder pain, urinary frequency, and life quality. Patients during flare episodes or taking antidepressant drugs were excluded. Urine samples from patients and healthy subjects were used to measure VEGF, VEGFR1, and serotonin urinary levels. The relation of VEGFR1 with serotonin and clinical parameters was assessed. Results:: Patients and healthy volunteers had a similar median age. No statistical differences in VEGF were detected. Urinary VEGFR1 was significantly lower in patients. Soluble VEGFR1 did not correlate to serotonin levels or clinical parameters. The urinary serotonin levels were similar between groups. Conclusion:: Urinary VEGFR1, but not urinary VEGF, might be a useful IC/BPS biomarker. Further investigation is necessary to confirm the present observation and validate the relationship of VEGFR1 with clinical parameters and serotonin. |
| format | Article |
| id | doaj-art-2eb453e2e30a4fd2b7912021dc506ed4 |
| institution | OA Journals |
| issn | 2772-9737 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Continence |
| spelling | doaj-art-2eb453e2e30a4fd2b7912021dc506ed42025-08-20T02:09:52ZengElsevierContinence2772-97372025-06-011410189810.1016/j.cont.2025.101898Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC?Pedro Abreu-Mendes0Rui Almeida Pinto1Diogo Dias2Francisco Cruz3Ana Charrua4Urology Department, Unidade Local de Saúde de São João, Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Portugal; RISE - HEALT@FMUP-TL2-neurosciences, Pain, neuro-urology and spine group, Faculty of Medicine, University of Porto, Portugal; Corresponding author.Urology Department, Unidade Local de Saúde de São João, Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Portugal; RISE - HEALT@FMUP-TL2-neurosciences, Pain, neuro-urology and spine group, Faculty of Medicine, University of Porto, PortugalUrology Department, Unidade Local de Saúde de São João, Porto, PortugalUrology Department, Unidade Local de Saúde de São João, Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Portugal; RISE - HEALT@FMUP-TL2-neurosciences, Pain, neuro-urology and spine group, Faculty of Medicine, University of Porto, PortugalBiomedicine Department, Faculty of Medicine, University of Porto, PortugalIntroduction:: Interstitial cystitis/bladder pain syndrome (IC/BPS) pathophysiology is not fully understood. Vascular endothelial growth factor (VEGF) has been implicated in bladder vasculature alterations and nociception, but the role of its soluble receptor, VEGFR1, remains poorly explored. This study aimed to determine whether urinary VEGF and VEGFR1 levels could be biomarkers for IC/BPS. As a post hoc analysis, we also examined VEGFR1 variation and its relationship with the clinical characteristics of IC/BPS patients and urinary serotonin levels. Material and Methods:: An observational cross-sectional pilot study was conducted after clearance from the ethics committee. Eighteen female IC/BPS patients and 19 healthy age-matched females without past urological conditions were included. ESSIC criteria were used to phenotype. The patient’s symptoms evaluated were bladder pain, urinary frequency, and life quality. Patients during flare episodes or taking antidepressant drugs were excluded. Urine samples from patients and healthy subjects were used to measure VEGF, VEGFR1, and serotonin urinary levels. The relation of VEGFR1 with serotonin and clinical parameters was assessed. Results:: Patients and healthy volunteers had a similar median age. No statistical differences in VEGF were detected. Urinary VEGFR1 was significantly lower in patients. Soluble VEGFR1 did not correlate to serotonin levels or clinical parameters. The urinary serotonin levels were similar between groups. Conclusion:: Urinary VEGFR1, but not urinary VEGF, might be a useful IC/BPS biomarker. Further investigation is necessary to confirm the present observation and validate the relationship of VEGFR1 with clinical parameters and serotonin.http://www.sciencedirect.com/science/article/pii/S2772973725001559Bladder Pain SyndromeInterstitial CystitisBiomarkerVEGFSerotonin |
| spellingShingle | Pedro Abreu-Mendes Rui Almeida Pinto Diogo Dias Francisco Cruz Ana Charrua Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC? Continence Bladder Pain Syndrome Interstitial Cystitis Biomarker VEGF Serotonin |
| title | Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC? |
| title_full | Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC? |
| title_fullStr | Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC? |
| title_full_unstemmed | Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC? |
| title_short | Soluble vascular endothelial growth factor receptor 1 (VEGFR1): A possible biomarker in BPS/IC? |
| title_sort | soluble vascular endothelial growth factor receptor 1 vegfr1 a possible biomarker in bps ic |
| topic | Bladder Pain Syndrome Interstitial Cystitis Biomarker VEGF Serotonin |
| url | http://www.sciencedirect.com/science/article/pii/S2772973725001559 |
| work_keys_str_mv | AT pedroabreumendes solublevascularendothelialgrowthfactorreceptor1vegfr1apossiblebiomarkerinbpsic AT ruialmeidapinto solublevascularendothelialgrowthfactorreceptor1vegfr1apossiblebiomarkerinbpsic AT diogodias solublevascularendothelialgrowthfactorreceptor1vegfr1apossiblebiomarkerinbpsic AT franciscocruz solublevascularendothelialgrowthfactorreceptor1vegfr1apossiblebiomarkerinbpsic AT anacharrua solublevascularendothelialgrowthfactorreceptor1vegfr1apossiblebiomarkerinbpsic |